Category: Market News

AB Dynamics (LSE:ABDP) reported a challenging first half, with revenue falling 16% to £48.8 million and the business moving to a statutory operating loss. The decline was largely attributed to delayed customer orders, softer-than-expected activity at its VadoTech testing services unit in China, and a £16.8 million exceptional charge, primarily linked to a non-cash impairment.

Despite the weaker top-line performance, the company preserved its adjusted operating margin at 18.6% and continued to generate strong cash flow, ending the period with net cash of £39.3 million. It also increased its interim dividend by 10% and reaffirmed expectations that full-year adjusted operating profit will meet market forecasts. This confidence is supported by improving order intake, a £47 million order book, and long-term demand trends tied to active safety systems and autonomous vehicle technologies.

Management has initiated a strategic review of the underperforming VadoTech China business, while placing greater emphasis on innovation and product alignment with evolving regulatory requirements and consumer testing standards. The company is also expanding its simulation capabilities, with early interest building around its Delta S3 Spin simulator.

AB Dynamics continues to highlight its diversified customer base, independence from specific OEMs and powertrain technologies, and strong pricing power as key strengths in navigating broader industry and geopolitical challenges. It remains focused on achieving medium-term targets of around 10% annual organic growth, operating margins above 20%, and sustained cash generation to support reinvestment.

From an investment perspective, the group’s solid financial fundamentals and positive management outlook provide support. However, weaker technical indicators point to a more cautious near-term trend, while valuation remains only moderately compelling, balancing the overall outlook.

More about AB Dynamics

AB Dynamics is a UK-based provider of advanced testing, simulation, and measurement solutions for the global transport sector. Its products and services are used by major automotive manufacturers, Tier 1 suppliers, and testing organisations to develop and validate vehicle dynamics, active safety systems, and autonomous driving technologies, including ADAS features.

Oxford Instruments (LSE:OXIG) expects to deliver full-year results in line with market expectations for the period ending 31 March 2026, driven by a stronger second-half performance. Group order intake rose 8% on an organic, constant-currency basis, resulting in a book-to-bill ratio of approximately 1.07. Revenue and margins also improved in the latter half, helped by earlier cost-saving measures within its Belfast imaging operations and continued share buyback activity, reinforcing confidence in the company’s growth trajectory.

The Advanced Technologies division was the key contributor, achieving roughly 30% organic growth in orders. This was fuelled by sustained demand for compound semiconductors and increasing engagement with high-volume manufacturing clients across the U.S. and Europe. A newly secured multi-year contract in April 2026 has further strengthened visibility, with the division’s order book now largely covering expected revenue for FY27 and extending into FY28.

Despite a more challenging macroeconomic backdrop and earlier tariff-related disruptions affecting the Imaging & Analysis segment, the company remains well positioned, supported by strong demand trends and improved operational efficiency.

From an investment standpoint, Oxford Instruments benefits from solid financial performance and proactive capital allocation, including share buybacks. However, relatively high valuation multiples and signs of overbought technical conditions suggest some caution may be warranted. While strategic initiatives and earnings momentum remain positives, attention to liquidity and profitability dynamics will be important going forward.

More about Oxford Instruments

Oxford Instruments is a FTSE 250-listed provider of advanced scientific technology, offering tools, software, and services to both academic and commercial customers globally. Its core focus areas include materials analysis, semiconductor technologies, and healthcare and life sciences, positioning the group to capitalise on growing investment in advanced materials, productivity enhancements, and decarbonisation efforts.

hVIVO (LSE:HVO) has entered into a clinical trial agreement with Traws Pharma to conduct a Phase 2a human challenge study evaluating tivoxavir marboxil, an oral, single-dose antiviral candidate designed to treat both seasonal and avian influenza.

The randomised, double-blind, placebo-controlled trial will be carried out at hVIVO’s quarantine facilities in Canary Wharf and is expected to enrol around 150 healthy participants through its FluCamp volunteer recruitment platform. The study will also utilise the company’s in-house virology laboratories, with the majority of associated revenue anticipated to be recognised during 2026.

This agreement highlights hVIVO’s strategy of leveraging its refined influenza human challenge model and integrated clinical capabilities to deliver faster and more controlled efficacy data compared with conventional field trials. The approach strengthens its role as a comprehensive clinical development partner. For Traws Pharma, the collaboration is intended to generate high-quality clinical data on the safety and effectiveness of its antiviral candidate, supporting further development in a significant global respiratory disease market.

From an investment perspective, the company’s outlook is supported by solid financial performance and an appealing valuation profile. Strong revenue growth and low leverage provide a favourable foundation within the biotechnology sector. While technical indicators point to positive momentum, the shares remain below key moving averages, which may indicate near-term resistance. A relatively low P/E ratio and a reasonable dividend yield further enhance its appeal to value and income-focused investors.

More about hVIVO plc

hVIVO plc is a specialised, full-service clinical development company and a global leader in human challenge trials. It works with seven of the world’s ten largest biopharmaceutical companies, offering an end-to-end platform that spans preclinical planning through to Phase II studies, alongside advanced laboratory services. The business operates across four core areas: consulting, clinical trials, human challenge studies, and laboratory services, with facilities in the UK and Germany.

Porvair (LSE:PRV) said trading in the first four months of 2026 remained in line with expectations, with revenue rising 5% on a constant currency basis. Performance was supported by the group’s diversified operations and stable demand across several core markets. Aerospace continued to show strong order momentum, while nuclear-related activity remained healthy. In contrast, European petrochemical markets and certain automotive segments were softer, and progress in life sciences and environmental laboratories was driven by scheduled product launches.

Within the Metal Melt Quality division, demand for aluminium and superalloy applications stayed resilient. The company’s £5.5 million aluminium cast house facility in Hendersonville, U.S., is progressing toward commissioning in the first half of the year. Meanwhile, the recently acquired Drache business is integrating smoothly and performing in line with expectations.

Despite ongoing geopolitical uncertainties and cost pressures, the board has maintained its full-year outlook. Management pointed to the strength of Porvair’s decentralised manufacturing model, which emphasises localised production, as well as a healthy pipeline of acquisition opportunities under review. The company also plans to host a capital markets event and provide a further update alongside its interim results later in the year.

From an investment standpoint, Porvair’s outlook is supported by solid profitability and a relatively low level of debt. However, this is balanced by more uncertain trends in revenue growth and free cash flow. Share price indicators are mixed, while valuation appears moderate, with a price-to-earnings ratio of around 21.9 and a relatively modest dividend yield.

More about Porvair

Porvair plc is a specialist filtration and environmental technology group focused on designing and manufacturing high-performance consumable filtration products. The company operates across three divisions: aerospace and industrial, laboratory, and metal melt quality. Its products serve a wide range of global markets, including aerospace, nuclear, petrochemical, life sciences, and metals processing, providing exposure to diverse industrial and scientific applications.

Amcomri Group (LSE:AMCO) delivered a record financial performance in 2025, with revenue rising 22% to £70.9 million, adjusted EBITDA increasing 19.3% to £9.2 million, and profit before tax more than doubling to £4.1 million. The results were driven by improved margins and the contribution from earnings-accretive acquisitions. Strong growth across both its Embedded Engineering and B2B Manufacturing divisions, combined with a broad and diversified customer base, helped cushion the impact of weaker conditions in certain markets, while supporting higher earnings per share and asset values despite an increase in net debt.

During the year, the group strengthened its capabilities through acquisitions, including EMC Elite Engineering and the Electronix business of Radnor Technologies—marking its first transaction outside the UK. These additions have supported operational synergies and enhanced management depth across the organisation. After the year-end, Amcomri agreed to acquire Enerveo’s National Compliance and Testing division, further expanding its footprint in electrical testing and compliance services.

Management noted that trading in 2026 has begun in line with expectations, with solid demand across key sectors such as rail electrification, defence, aerospace, power generation, and broader energy markets continuing to support activity.

From an outlook perspective, the company benefits from strong financial momentum and positive share price trends. However, these strengths are balanced by a relatively high valuation, which may indicate limited upside. The lack of recent earnings call insights or major corporate events means these factors do not materially influence the overall investment view.

More about Amcomri Group Plc

Amcomri Group Plc is a UK-focused engineering services and industrial manufacturing business operating under a “Buy, Improve, Build” strategy. Through its Embedded Engineering and B2B Manufacturing segments, the group delivers critical technical services and specialised manufacturing solutions to clients in sectors such as infrastructure, transport, industrials, and energy—often within highly regulated and safety-critical environments.

The company focuses on acquiring small and medium-sized businesses with strong positions in niche B2B markets, particularly in situations involving owner-manager succession. It aims to enhance performance through integration and operational improvements. Built through 19 acquisitions, including multiple bolt-on deals, Amcomri maintains a diversified portfolio that helps provide resilience across different economic cycles.

ProCook (LSE:PROC) posted a robust fourth quarter, with revenue climbing 19.2% to £18.5 million and like-for-like sales increasing 9.9%. Growth was supported by strong double-digit gains across both its retail stores and ecommerce channels, alongside contributions from newly opened locations.

For the full year, the company achieved record revenue of £85.5 million, representing a 23% year-on-year increase and exceeding market expectations. ProCook also significantly outpaced the broader UK kitchenware sector, outperforming it by around 20 percentage points while continuing to expand its market share.

Earnings performance showed improvement as well, with EBITDA projected to come in slightly ahead of forecasts, while operating profit and profit before tax were broadly in line with expectations. This came despite some headwinds from newer stores, which are still maturing, and foreign exchange pressures. The balance sheet remains solid, with £4.4 million in net cash and total available liquidity of £20.4 million, providing the company with flexibility to invest further in store expansion, marketing initiatives, technology upgrades, and AI capabilities. Management continues to target 100 stores, £100 million in revenue, and a 10% operating margin over the medium term.

Looking ahead, the company’s outlook is supported by improving operational performance and strong cash generation, along with positive share price momentum trading above key moving averages. However, these strengths are partly offset by elevated balance sheet leverage and weaker valuation signals, including a negative P/E ratio and the absence of a dividend yield.

More about ProCook Group PLC

ProCook Group PLC is a UK-based direct-to-consumer kitchenware brand focused on designing, developing, and selling high-quality own-brand products at competitive prices. Headquartered in Gloucester, the company operates through its website and a network of 78 stores across the UK. Established over 30 years ago, ProCook employs more than 700 people and has been listed on the London Stock Exchange since 2021.

Serabi Gold (LSE:SRB) delivered first-quarter 2026 gold production of 12,042 ounces, marking a 20% increase compared to the same period last year. The company also reported a cash position of $64.4 million and is now debt-free following the repayment of a $5.3 million facility. Management reiterated its full-year production target of 53,000 to 57,000 ounces, supported by solid operational performance at both Palito and Coringa, where ongoing mechanisation and ore-sorting initiatives are improving efficiency and boosting grades.

In response to capacity constraints and a favourable gold price environment, Serabi has initiated the installation of a fourth ball mill at the Palito Complex. This upgrade is expected to lift processing capacity to around 330,000 tonnes per year by 2027, allowing the company to treat lower-grade stockpiles and potentially restart operations at the São Chico satellite mine.

At Coringa, progress continues toward securing a full mining licence, with key approvals related to land use and indigenous stakeholders moving forward. Meanwhile, the company is addressing safety concerns after two recent underground fatalities by increasing on-site safety personnel and commissioning an independent external review, highlighting a renewed focus on ESG standards and operational risk controls.

From a financial standpoint, Serabi’s outlook is underpinned by strong margins, growing earnings potential, and minimal leverage, alongside an attractive valuation reflected in a relatively low P/E ratio. However, these strengths are somewhat offset by softer technical indicators, with the shares trading below short-term moving averages and showing limited momentum.

More about Serabi Gold

Serabi Gold is a Brazil-focused gold producer engaged in exploration, development, and mining activities. Its core assets include the Palito Complex and the Coringa underground project in the Tapajós region. The company’s strategy emphasizes expanding existing operations, optimizing plant capacity, and growing its resource base, with a goal of reaching at least 1.5 million ounces of gold resources by the end of 2026.

Sunda Energy plc (LSE:SNDA) has taken a significant step toward expanding its footprint in New Zealand by paying an initial US$1.5 million deposit to Matahio Ventures. The payment relates to a conditional agreement to acquire Matahio Energy NZ Limited, a company that holds and operates a mix of producing and exploration oil and gas permits across the country.

This transaction highlights Sunda’s broader strategy to strengthen its presence in the Asia-Pacific region, particularly by adding assets that are already producing as well as those still in the appraisal phase. By doing so, the company aims to build a more balanced portfolio that combines near-term output with longer-term development potential.

As part of the acquisition process, Sunda has submitted an application to New Zealand regulators seeking approval for a change of control involving the permit-holding operating entities. This step is required under the Crown Minerals Act, and securing this consent will be essential before the deal can be finalized and the assets fully integrated into Sunda’s operations.

From an investment perspective, the company continues to face pressure from its financial profile. It currently reports no revenue and widening losses, alongside ongoing cash outflows, although its leverage remains relatively low. While recent share price momentum has offered some technical support, overbought indicators suggest caution. Valuation also remains constrained given the lack of profitability and absence of dividend prospects.

More about Sunda Energy plc

Sunda Energy plc is an AIM-listed oil and gas exploration and appraisal company focused on the Asia-Pacific region. Its strategy centers on building a diversified portfolio of upstream assets, combining exploration opportunities with producing fields, and expanding its regional presence through targeted acquisitions such as its planned entry into New Zealand.